249 related articles for article (PubMed ID: 34266857)
1. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
[TBL] [Abstract][Full Text] [Related]
2. Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
Ulusan AM; Rajendran P; Dashwood WM; Yavuz OF; Kapoor S; Gustafson TA; Savage MI; Brown PH; Sei S; Mohammed A; Vilar E; Dashwood RH
Cancer Prev Res (Phila); 2021 Mar; 14(3):325-336. PubMed ID: 33277315
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
4. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
[TBL] [Abstract][Full Text] [Related]
5. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
Samadder NJ; Neklason DW; Boucher KM; Byrne KR; Kanth P; Samowitz W; Jones D; Tavtigian SV; Done MW; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Davis R; Topham MK; Lynch P; Strait E; McKinnon W; Burt RW; Kuwada SK
JAMA; 2016 Mar 22-29; 315(12):1266-75. PubMed ID: 27002448
[TBL] [Abstract][Full Text] [Related]
6. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis.
Hisamuddin IM; Wehbi MA; Schmotzer B; Easley KA; Hylind LM; Giardiello FM; Yang VW
Cancer Epidemiol Biomarkers Prev; 2005 Oct; 14(10):2366-9. PubMed ID: 16214918
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
Delker DA; Wood AC; Snow AK; Samadder NJ; Samowitz WS; Affolter KE; Boucher KM; Pappas LM; Stijleman IJ; Kanth P; Byrne KR; Burt RW; Bernard PS; Neklason DW
Cancer Prev Res (Phila); 2018 Jan; 11(1):4-15. PubMed ID: 29109117
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
Cruz-Correa M; Hylind LM; Romans KE; Booker SV; Giardiello FM
Gastroenterology; 2002 Mar; 122(3):641-5. PubMed ID: 11874996
[TBL] [Abstract][Full Text] [Related]
10. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors.
Giardiello FM; Offerhaus JA; Tersmette AC; Hylind LM; Krush AJ; Brensinger JD; Booker SV; Hamilton SR
Gut; 1996 Apr; 38(4):578-81. PubMed ID: 8707091
[TBL] [Abstract][Full Text] [Related]
11. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model.
Williamson T; Bai RY; Staedtke V; Huso D; Riggins GJ
Oncotarget; 2016 Oct; 7(42):68571-68584. PubMed ID: 27612418
[TBL] [Abstract][Full Text] [Related]
12. Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis.
Matsumoto T; Nakamura S; Esaki M; Yao T; Iida M
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):251-7. PubMed ID: 16460482
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal analysis of colon crypt stem cell dynamics in sulindac treated Familial Adenomatous Polyposis patients.
Ma H; Brosens LAA; Elias SG; Morsink FHM; Nijman IJ; Hylind LM; Montgomery EA; Offerhaus GJA; Giardiello FM; de Leng WWJ
Sci Rep; 2017 Sep; 7(1):11972. PubMed ID: 28931879
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis.
Giardiello FM; Spannhake EW; DuBois RN; Hylind LM; Robinson CR; Hubbard WC; Hamilton SR; Yang VW
Dig Dis Sci; 1998 Feb; 43(2):311-6. PubMed ID: 9512123
[TBL] [Abstract][Full Text] [Related]
15. Sulindac in familial adenomatous polyposis: evaluation by nuclear morphometry.
Fernández-López F; Conde-Freire R; Cadarso-Suárez C; García-Iglesias J; Puente-Domínguez JL; Potel-Lesquereux J
Eur J Surg; 2001 May; 167(5):375-81. PubMed ID: 11419555
[TBL] [Abstract][Full Text] [Related]
16. Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC.
Faux MC; Weinstock J; Gogos S; Prato E; Azimpour AI; O'Keefe R; Cathcart-King Y; Garnham AL; Ernst M; Preaudet A; Christie M; Putoczki TL; Buchert M; Burgess AW
Cancer Res Commun; 2022 Feb; 2(2):66-77. PubMed ID: 36860494
[TBL] [Abstract][Full Text] [Related]
17. miR-155 Is Downregulated in Familial Adenomatous Polyposis and Modulates WNT Signaling by Targeting AXIN1 and TCF4.
Prossomariti A; Piazzi G; D'Angelo L; Miccoli S; Turchetti D; Alquati C; Montagna C; Bazzoli F; Ricciardiello L
Mol Cancer Res; 2018 Dec; 16(12):1965-1976. PubMed ID: 30072583
[TBL] [Abstract][Full Text] [Related]
18. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
Koornstra JJ; Rijcken FE; Oldenhuis CN; Zwart N; van der Sluis T; Hollema H; deVries EG; Keller JJ; Offerhaus JA; Giardiello FM; Kleibeuker JH
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1608-12. PubMed ID: 16030090
[TBL] [Abstract][Full Text] [Related]
19. Sulindac for periampullary polyps in FAP patients.
Richard CS; Berk T; Bapat BV; Haber G; Cohen Z; Gallinger S
Int J Colorectal Dis; 1997; 12(1):14-8. PubMed ID: 9112144
[TBL] [Abstract][Full Text] [Related]
20. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines.
Boon EM; Keller JJ; Wormhoudt TA; Giardiello FM; Offerhaus GJ; van der Neut R; Pals ST
Br J Cancer; 2004 Jan; 90(1):224-9. PubMed ID: 14710233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
